|
1
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar
|
|
2
|
de Ruijter TC, Veeck J, de Hoon JP, van
Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative
breast cancer. J Cancer Res Clin Oncol. 137:183–192.
2011.PubMed/NCBI
|
|
3
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. New Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peddi PF, Ellis MJ and Ma C: Molecular
basis of triple negative breast cancer and implications for
therapy. Int J Breast Cancer. 2012:2171852012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yao-Lung K, Dar-Ren C and Tsai-Wang C:
Clinicopathological features of triple-negative breast cancer in
Taiwanese women. Int J Clin Oncol. 16:500–505. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hall RE, Birrell SN, Tilley WD and
Sutherland RL: MDA-MB-453, an androgen-responsive human breast
carcinoma cell line with high level androgen receptor expression.
Eur J Cancer. 30A:484–490. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lehmann BD, Bauer JA, Chen X, et al:
Identification of human triple-negative breast cancer subtypes and
preclinical models for selection of targeted therapies. J Clin
Invest. 121:2750–2767. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh G, Odriozola L, Guan H, Kennedy CR
and Chan AM: Characterization of a novel PTEN mutation in
MDA-MB-453 breast carcinoma cell line. BMC Cancer. 11:4902011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fornier M and Fumoleau P: The paradox of
triple negative breast cancer: novel approaches to treatment.
Breast J. 18:41–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gucalp A and Traina TA: Triple-negative
breast cancer: adjuvant therapeutic options. Chemother Res Pract.
2011:6962082011.PubMed/NCBI
|
|
11
|
Yagata H, Kajiura Y and Yamauchi H:
Current strategy for triple-negative breast cancer: appropriate
combination of surgery, radiation, and chemotherapy. Breast Cancer.
18:165–173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Minami CA, Chung DU and Chang HR:
Management options in triple-negative breast cancer. Breast Cancer
(Auckl). 5:175–199. 2011.PubMed/NCBI
|
|
13
|
Rakha EA and Chan S: Metastatic
triple-negative breast cancer. Clin Oncol (R Coll Radiol).
23:587–600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Steponaviciene L, Lachej-Mikeroviene N,
Smailyte G, Aleknavicius E, Meskauskas R and Didziapetriene J:
Triple negative breast cancer: adjuvant chemotherapy effect on
survival. Adv Med Sci. 56:285–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu J, Li S, Jia W and Su F: Response and
prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in
patients with triple-negative breast cancer. J Cancer Res Clin
Oncol. 137:1505–1510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brady-West DC and McGrowder DA: Triple
negative breast cancer: therapeutic and prognostic implications.
Asian Pac J Cancer Prev. 12:2139–2143. 2011.PubMed/NCBI
|
|
17
|
Lee F, Jure-Kunkel MN and Salvati ME:
Synergistic activity of ixabepilone plus other anticancer agents:
preclinical and clinical evidence. Ther Adv Med Oncol. 3:11–25.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fornier M: Ixabepilone plus capecitabine
for breast cancer patients with an early metastatic relapse after
adjuvant chemotherapy: two clinical trials. Clin Breast Cancer.
10:352–358. 2010. View Article : Google Scholar
|
|
19
|
Perez EA, Patel T and Moreno-Aspitia A:
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative)
breast cancer. Breast cancer Res Treat. 121:261–271. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Fan Y and Xu B: Ixabepilone plus
capecitabine for Chinese patients with metastatic breast cancer
progressing after anthracycline and taxane treatment. Cancer
Chemother Pharmacol. 66:597–603. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jassem J, Fein L, Karwal M, et al:
Ixabepilone plus capecitabine in advanced breast cancer patients
with early relapse after adjuvant anthracyclines and taxanes: a
pooled subset analysis of two phase III studies. Breast. 21:89–94.
2012. View Article : Google Scholar
|
|
22
|
Li L, Li J, Yang K, et al: Ixabepilone
plus capecitabine with capecitabine alone for metastatic breast
cancer. Future Oncol. 6:201–207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roché H, Conte P, Perez EA, et al:
Ixabepilone plus capecitabine in metastatic breast cancer patients
with reduced performance status previously treated with
anthracyclines and taxanes: a pooled analysis by performance status
of efficacy and safety data from 2 phase III studies. Breast Cancer
Res Treat. 125:755–765. 2011.
|
|
24
|
Denduluri N and Swain S: Ixabepilone:
clinical role in metastatic breast cancer. Clin Breast Cancer.
11:139–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sparano JA, Vrdoljak E, Rixe O, et al:
Randomized phase III trial of ixabepilone plus capecitabine versus
capecitabine in patients with metastatic breast cancer previously
treated with an anthracycline and a taxane. J Clin Oncol.
28:3256–3263. 2010. View Article : Google Scholar
|
|
26
|
Yu Z, Baserga R, Chen L, Wang C, Lisanti
MP and Pestell RG: microRNA, cell cycle, and human breast cancer.
Am J Pathol. 176:1058–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shah MY, Pan X, Fix LN, Farwell MA and
Zhang B: 5-Fluorouracil drug alters the microRNA expression
profiles in MCF-7 breast cancer cells. J Cell Physiol.
226:1868–1878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kutanzi KR, Yurchenko OV, Beland FA,
Checkhun VF and Pogribny IP: MicroRNA-mediated drug resistance in
breast cancer. Clin Epigenetics. 2:171–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Andorfer CA, Necela BM, Thompson EA and
Perez EA: MicroRNA signatures: clinical biomarkers for the
diagnosis and treatment of breast cancer. Trends in Mol Med.
17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang L and Wang J: MicroRNA-mediated
breast cancer metastasis: from primary site to distant organs.
Oncogene. 31:2499–2511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Radojicic J, Zaravinos A, Vrekoussis T,
Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression
analysis in triple-negative (ER, PR and Her2/neu) breast cancer.
Cell Cycle. 10:507–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rothé F, Ignatiadis M, Chaboteaux C, et
al: Global microRNA expression profiling identifies MiR-210
associated with tumor proliferation, invasion and poor clinical
outcome in breast cancer. PloS One. 6:e209802011.
|
|
33
|
Song B, Wang C, Liu J, et al: MicroRNA-21
regulates breast cancer invasion partly by targeting tissue
inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res.
29:292010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang L, Wei L, Zhao W, et al:
Down-regulation of osteopontin expression by RNA interference
affects cell proliferation and chemotherapy sensitivity of breast
cancer MDA-MB-231 cells. Mol Med Rep. 5:373–376. 2012.PubMed/NCBI
|
|
35
|
Liu H, Cao YD, Ye WX and Sun YY: Effect of
microRNA-206 on cytoskeleton remodelling by downregulating Cdc42 in
MDA-MB-231 cells. Tumori. 96:751–755. 2010.PubMed/NCBI
|
|
36
|
Wang L, Shan BE, Sang MX, Lian YS, Wang B
and Ding CY: Effect of microRNA-mediated p65 gene silencing on the
proliferation and apoptosis of human breast cancer MDA-MB-231
cells. Nan Fang Yi Ke Da Xue Xue Bao. 31:1742–1747. 2011.(In
Chinese).
|
|
37
|
Varkonyi-Gasic E and Hellens RP:
Quantitative stem-loop RT-PCR for detection of microRNAs. Methods
Mol Biol. 744:145–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Scully OJ, Bay BH, Yip G and Yu Y: Breast
cancer metastasis. Cancer Genomics Proteomics. 9:311–320. 2012.
|
|
39
|
Iorio MV, Ferracin M, Liu CG, et al:
MicroRNA gene expression deregulation in human breast cancer.
Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Calin GA and Croce CM: MicroRNA-cancer
connection: the beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jeyaseelan K, Herath WB and Armugam A:
MicroRNAs as therapeutic targets in human diseases. Expert Opin
Ther Targets. 11:1119–1129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Walko CM and Lindley C: Capecitabine: a
review. Clin Ther. 27:23–44. 2005. View Article : Google Scholar
|
